Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI reads chest X-Rays to predict lung cancer risk

NCT ID NCT05817110

Diagnosis Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 21, 2026 · Updated 2 times

Summary

This study is testing an artificial intelligence (AI) program called qXR that analyzes chest X-rays to give a lung nodule malignancy score — a number that indicates how likely a lung nodule is to be cancer. Researchers will compare the AI's score to the results of CT scans and radiologist reviews in about 712 adults aged 35 and older who have a lung nodule found on X-ray. The goal is to see if the AI can reliably tell high-risk from low-risk nodules, which could help doctors decide who needs a CT scan and who can safely wait.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AI software (qXR) that analyzes chest X-rays to give a lung nodule malignancy score
What this could lead to
If successful, this AI tool could help doctors quickly identify which lung nodules need further testing, potentially catching lung cancer earlier and reducing unnecessary CT scans.
What could go wrong
This is an observational study, not a treatment trial. The AI may not be accurate enough in real-world settings, and results may not apply to all populations or healthcare systems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

712 people

The number who actually took part.

Started

Apr 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults patient (35years or more) coming for chest X-ray at the institution.

Ages

35 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female patients aged \>35 years * Patients diagnosed with incidental pulmonary nodule (IPN) on CXR (chest x-ray) by qXR and confirmed by the radiologist at the site with nodule size ≥8 and ≤30 mm. Exclusion Criteria: * Any medical or other contraindications for a CT scan * Nondigital (chest x-ray)CXR * CT scan is done more than 6 months after (chest x-ray) CXR * Patients with already diagnosed lung cancer * The patients referred for an X-Ray for a suspicious Lung cancer * A patient who already participated in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung malignancy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung cancer lung carcinoma lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung malignancy

Contacts and locations

Locations

  • Research Site

    Alexandria, Egypt

  • Research Site

    Cairo, Egypt

  • Research Site

    Gurugram, Haryana, 122001, India

  • Research Site

    New Delhi, National Capital Territory of Delhi, 110005, India

  • Research Site

    New Delhi, National Capital Territory of Delhi, 110017, India

  • Research Site

    New Delhi, National Capital Territory of Delhi, 201012, India

  • Research Site

    Hyderabad, Telangana, 500003, India

  • Research Site

    Bangalore, 560011, India

  • Research Site

    Bangalore, 560038, India

  • Research Site

    Chennai, 600026, India

  • Research Site

    Chennai, 600040, India

  • Research Site

    Chennai, 600045, India

  • Research Site

    Chennai, 600053, India

  • Research Site

    Chennai, 600116, India

  • Research Site

    Kolkata, 700025, India

  • Research Site

    Mumbai, 400069, India

  • Research Site

    Pune, 411011, India

  • Research Site

    Surabaya, 60286, Indonesia

  • Research Site

    Monterrey, Nuevo León, 64460, Mexico

  • Research Site

    Mexico City, 6720, Mexico

  • Research Site

    Ankara, Turkey, 06100, Turkey (Türkiye)

  • Research Site

    Mersin, Turkey, 33010, Turkey (Türkiye)